Drugs / BOSAKITUG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05114889 | Oct 2021 → Feb 2023 | atopic eczema | Biosion, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05932654 | Jul 2023 → Sep 2024 | atopic eczema | Biosion, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOSAKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314979 ↗ |
| Known as | BSI-045B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05932654 ↗ |
| Modality | Monoclonal antibody | “BSI-045B mAb Injection” NCT05114889 ↗ |
| Route | Subcutaneous | “BSI-045B will be administered weekly, subcutaneously” NCT05114889 ↗ |